Patents by Inventor Ramon Alemany Bonastre

Ramon Alemany Bonastre has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • ADENOVIRUS COMPRISING AN ALBUMIN-BINDING MOIETY
    Publication number: 20230331786
    Abstract: The invention relates to a recombinant adenovirus comprising an albumin-binding moiety on the outer surface of the adenoviral hexon protein, pharmaceutical compositions containing it and its medical use. Particularly, the invention relates to an oncolytic adenovirus comprising a sequence encoding an albumin-binding moiety inserted in the hypervariable region 1 (HVR1) of the hexon protein coding sequence and its use in the prevention and/or treatment of cancer.
    Type: Application
    Filed: January 10, 2023
    Publication date: October 19, 2023
    Inventors: Ramon Alemany Bonastre, Luis Alfonso Rojas Expósito
  • Adenovirus comprising an albumin-binding moiety
    Patent number: 11578104
    Abstract: The invention relates to a recombinant adenovirus comprising an albumin-binding moiety on the outer surface of the adenoviral hexon protein, pharmaceutical compositions containing it and its medical use. Particularly, the invention relates to an oncolytic adenovirus comprising a sequence encoding an albumin-binding moiety inserted in the hypervariable region 1 (HVR1) of the hexon protein coding sequence and its use in the prevention and/or treatment of cancer.
    Type: Grant
    Filed: February 19, 2020
    Date of Patent: February 14, 2023
    Assignees: Fundació Institut D'lnvestigació Biomedica De Bellvitge (í DIBELL), INSTITUT CATALA D'ONCOLOGIA (ICO)
    Inventors: Ramon Alemany Bonastre, Luis Alfonso Rojas Expósito
  • ADENOVIRUS COMPRISING AN ALBUMIN-BINDING MOIETY
    Publication number: 20200181208
    Abstract: The invention relates to a recombinant adenovirus comprising an albumin-binding moiety on the outer surface of the adenoviral hexon protein, pharmaceutical compositions containing it and its medical use. Particularly, the invention relates to an oncolytic adenovirus comprising a sequence encoding an albumin-binding moiety inserted in the hypervariable region 1 (HVR1) of the hexon protein coding sequence and its use in the prevention and/or treatment of cancer.
    Type: Application
    Filed: February 19, 2020
    Publication date: June 11, 2020
    Inventors: Ramon Alemany Bonastre, Luis Alfonso Rojas Expósito
  • Adenovirus comprising an albumin-binding moiety
    Patent number: 10604549
    Abstract: The invention relates to a recombinant adenovirus comprising an albumin-binding moiety on the outer surface of the adenoviral hexon protein, pharmaceutical compositions containing it and its medical use. Particularly, the invention relates to an oncolytic adenovirus comprising a sequence encoding an albumin-binding moiety inserted in the hypervariable region 1 (HVR1) of the hexon protein coding sequence and its use in the prevention and/or treatment of cancer.
    Type: Grant
    Filed: April 30, 2015
    Date of Patent: March 31, 2020
    Assignees: FUNDACIÓ INSTITUT D'INVESTIGACIÓ BIOMÈDICA DE BELLVITGE (IDIBELL), INSTITUT CATALÀ D'ONCOLOGIA (ICO)
    Inventors: Ramon Alemany Bonastre, Luis Alfonso Rojas Expósito
  • ONCOLYTIC ADENOVIRUSES FOR TREATING CANCER
    Publication number: 20190345204
    Abstract: The invention is related to an oncolytic adenovirus that comprises a sequence encoding a hyaluronidase enzyme inserted in its genome. This adenovirus spreads more efficiently in the tumour mass and therefore the oncolytic effect is increased. Injecting the oncolytic adenovirus of the invention endovenously, tumour volume regressions are obtained. Therefore the oncolytic adenovirus of the present invention is useful for the treatment of a cancer or a pre-malignant state of cancer.
    Type: Application
    Filed: May 7, 2019
    Publication date: November 14, 2019
    Inventors: Sònia Guedan Carrió, Manel Maria Cascallo Piqueras, Ramon Alemany Bonastre
  • ONCOLYTIC ADENOVIRUSES FOR CANCER TREATMENT
    Publication number: 20190183946
    Abstract: The invention relates to an oncolytic adenovirus for the treatment of cancer, containing a human DNA sequence isolating a promoter conferring selective expression on an adenoviral gene. Said adenovirus can also contain a sequence that optimizes the protein translation of an adenoviral gene regulated by a promoter conferring tumor selectivity. The invention is suitable for use in the treatment of cancer.
    Type: Application
    Filed: July 5, 2018
    Publication date: June 20, 2019
    Inventors: Ramon Alemany Bonastre, Juan Jose Rojas Exposito, Manel Maria Cascallo Piqueras
  • Oncolytic adenoviruses for treating cancer
    Patent number: 10316065
    Abstract: The invention is related to an oncolytic adenovirus that comprises a sequence encoding a hyaluronidase enzyme inserted in its genome. This adenovirus spreads more efficiently in the tumour mass and therefore the oncolytic effect is increased. Injecting the oncolytic adenovirus of the invention endovenously results in tumour volume regressions. Therefore, the oncolytic adenovirus of the present invention is useful for the treatment of a cancer or a pre-malignant state of cancer.
    Type: Grant
    Filed: May 5, 2010
    Date of Patent: June 11, 2019
    Assignees: Fundacio Institut d Investigacio Biomedica de Bellvitge (IDIBELL), Institut Catala D Oncologia
    Inventors: Sònia Guedan Carrió, Manel Maria Cascallo Piqueras, Ramon Alemany Bonastre
  • Oncolytic adenoviruses for cancer treatment
    Patent number: 10016470
    Abstract: The invention relates to an oncolytic adenovirus for the treatment of cancer, containing a human DNA sequence isolating a promoter conferring selective expression on an adenoviral gene. Said adenovirus can also contain a sequence that optimizes the protein translation of an adenoviral gene regulated by a promoter conferring tumor selectivity. The invention is suitable for use in the treatment of cancer.
    Type: Grant
    Filed: May 2, 2016
    Date of Patent: July 10, 2018
    Assignee: DNATRIX, INC.
    Inventors: Ramon Alemany Bonastre, Juan Jose Rojas Exposito, Manel Maria Cascallo Piqueras
  • ADENOVIRUS COMPRISING AN ALBUMIN-BINDING MOIETY
    Publication number: 20170051022
    Abstract: The invention relates to a recombinant adenovirus comprising an albumin-binding moiety on the outer surface of the adenoviral hexon protein, pharmaceutical compositions containing it and its medical use. Particularly, the invention relates to an oncolytic adenovirus comprising a sequence encoding an albumin-binding moiety inserted in the hypervariable region 1 (HVR1) of the hexon protein coding sequence and its use in the prevention and/or treatment of cancer.
    Type: Application
    Filed: April 30, 2015
    Publication date: February 23, 2017
    Inventors: Ramon Alemany Bonastre, Luis Alfonso Rojas Expósito
  • Oncolytic Adenoviruses for Cancer Treatment
    Publication number: 20160354420
    Abstract: The invention relates to an oncolytic adenovirus for the treatment of cancer, containing a human DNA sequence isolating a promoter conferring selective expression on an adenoviral gene. Said adenovirus can also contain a sequence that optimizes the protein translation of an adenoviral gene regulated by a promoter conferring tumor selectivity. The invention is suitable for use in the treatment of cancer.
    Type: Application
    Filed: May 2, 2016
    Publication date: December 8, 2016
    Inventors: Ramon Alemany Bonastre, Juan Jose Rojas Exposito, Manel Maria Cascallo Piqueras
  • Oncolytic Adenoviruses for Cancer Treatment
    Publication number: 20150071881
    Abstract: The invention relates to an oncolytic adenovirus for the treatment of cancer, containing a human DNA sequence isolating a promoter conferring selective expression on an adenoviral gene. Said adenovirus can also contain a sequence that optimizes the protein translation of an adenoviral gene regulated by a promoter conferring tumor selectivity. The invention is suitable for use in the treatment of cancer.
    Type: Application
    Filed: July 10, 2014
    Publication date: March 12, 2015
    Inventors: Ramon Alemany Bonastre, Juan Jose Rojas Exposito, Manel Maria Cascallo Piqueras
  • Adenovirus with mutations in the endoplasmic reticulum retention domain of the E3-19K protein and their use in cancer treatment
    Patent number: 8974777
    Abstract: The present invention relates to an adenovirus wherein said adenovirus replicates and it contains a mutation in the endoplasmic reticulum retention domain of E3-19K, and to the use of said mutant in treating cancer. Said mutant virus may also contain other mutations and insertions of DNA sequences used to confer selectivity and antitumor potency. The invention has application in the field of cancer therapy.
    Type: Grant
    Filed: September 10, 2009
    Date of Patent: March 10, 2015
    Assignee: Institut CataláD'oncologia
    Inventors: Manel Maria Cascallo Piqueras, Alena Gros, Ramon Alemany Bonastre
  • Adenoviruses Mutated In The VA Genes For Cancer Treatment
    Publication number: 20110053249
    Abstract: This invention refers to the use of an adenovirus for cancer treatment, being this adenovirus defective in its virus-associated (VA) RNAs. Said adenovirus has a mutation in the VAI or VAII gene sequence or both. This adenovirus may also have mutations in the sequences controlling expression of the VA RNAs.
    Type: Application
    Filed: May 27, 2010
    Publication date: March 3, 2011
    Inventors: Ramon Alemany Bonastre, Manel Maria Cascallo Piqueras
  • Adenovirus With Mutations in the Endoplasmic Reticulum Retention Domain of the E3-19K Protein and Their Use in Cancer Treatment
    Publication number: 20100124546
    Abstract: The present invention relates to an adenovirus wherein said adenovirus replicates and it contains a mutation in the endoplasmic reticulum retention domain of E3-19K, and to the use of said mutant in treating cancer. Said mutant virus may also contain other mutations and insertions of DNA sequences used to confer selectivity and antitumor potency. The invention has application in the field of cancer therapy.
    Type: Application
    Filed: September 10, 2009
    Publication date: May 20, 2010
    Applicant: Institut Catala D'oncologia
    Inventors: Manel Maria Cascallo Piqueras, Alena Gros, Ramon Alemany Bonastre
  • Oncolytic Adenoviruses for Cancer Treatment
    Publication number: 20090311219
    Abstract: The invention relates to an oncolytic adenovirus for the treatment of cancer, containing a human DNA sequence isolating a promoter conferring selective expression on an adenoviral gene. Said adenovirus can also contain a sequence that optimizes the protein translation of an adenoviral gene regulated by a promoter conferring tumor selectivity. The invention is suitable for use in the treatment of cancer.
    Type: Application
    Filed: August 1, 2008
    Publication date: December 17, 2009
    Inventors: Ramon Alemany Bonastre, Juan Jose Rojas Exposito, Manel Maria Cascallo Piqueras
  • Use of adenoviruses mutated in the VA genes for cancer treatment
    Patent number: 7344711
    Abstract: This invention refers to the use of an adenovirus for cancer treatment, being this adenovirus defective in its virus-associated (VA) RNAs. Said adenovirus has a mutation in the VAI or VAII gene sequence or both. This adenovirus may also have mutations in the sequences controlling expression of the VA RNAs.
    Type: Grant
    Filed: March 25, 2003
    Date of Patent: March 18, 2008
    Assignee: Oncolytics Biotech Inc.
    Inventors: Ramon Alemany Bonastre, Manel Maria Piqueras